Phase II study: Radiotherapy dose increase to hypoxic NSCLC lesions [using PET/CT]
Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET) radiotracer that is widely used to diagnose hypoxia (insufficient oxygen supply to tissue), and non-small cell lung cancer (NSCLC) patients with FMISO uptake are known to face a poor prognosis. A multicenter French Phase II study featured in the July issue of The Journal of Nuclear Medicine (JNM) investigated whether a selective radiotherapy (RT) dose increase to tumor areas with significant FMISO uptake in NSCLC patients could improve outcomes. {read more here}
Tracer uptake on PET/CT imaging showed significant association with clinical outcomes of bone-involved metastatic castration resistant prostate cancer (mCRPC), a small clinical trial showed. {read more here}
CXCR4 is highly produced in more than 20 tumor types, promoting tumor growth and progression, tumor invasiveness, and metastasis. That is what studies in lab-grown cells have shown. But a novel PET/CT imaging agent targeting CXCR4 in cancer mouse models and patients has shown otherwise. {read more here}
Value is advancing nuclear medicine imaging modalities that have a long history of providing clinicians unique views into their patients’ cellular and molecular levels, driving earlier diagnoses. Current innovation is bringing unprecedented specificity and sensitivity to molecular imaging, resulting in many benefits. {read more here}